Pyridine, 2-fluoro-5-propyl- | 1823921-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Pyridine, 2-fluoro-5-propyl-
• 英文别名: 2-fluoro-5-propylpyridine
• CAS: 1823921-76-1
• 化学式: C₈H₁₀FN
• 分子量: 139.17
• InChiKey: HFQTXPZAWFBWLM-UHFFFAOYSA-N

物化性质

• 沸点：
  199.3±20.0 °C(Predicted)
• 密度：
  1.021±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
• NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS
  申请人：Riguet Eric

  公开号：US20100004246A1

  公开（公告）日：2010-01-07

  The present invention provides novel compounds of formula I wherein W 1 , W 2 , W 3 , W 4 , W 5 , B, X 1 , X 2 , X 3 , X 4 , X 5 , E and L are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype B (“GABA B ”) positive allosteric modulators (enhancers), which are useful to provide methods of treating or preventing diseases or disorders, including treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, panic disorder, posttraumatic stress disorders, urge urinary incontinence, gastroesophageal reflux disease, transient lower oesophageal sphincter relaxations, functional gastrointestinal disorders and irritable bowel syndrome.

  本发明提供了式I的新化合物，其中W1、W2、W3、W4、W5、B、X1、X2、X3、X4、X5、E和L的定义如本文所述；发明的化合物是γ-氨基丁酸受体亚型B（“GABAB”）正向变构调节剂（增强剂），可用于提供治疗或预防疾病或疾病的方法，包括焦虑、抑郁、癫痫、精神分裂症、认知障碍、痉挛和骨骼肌肌紧张、脊髓损伤、多发性硬化、肌萎缩性侧索硬化、脑瘫、神经痛和与可卡因和尼古丁相关的渴望、惊恐障碍、创伤后应激障碍、急迫性尿失禁、胃食管反流病、暂时性下食管括约肌松弛、功能性胃肠疾病和肠易激综合征的治疗。
• MIXTURES OF MESOIONIC PESTICIDES
  申请人：Holyoke, JR. Caleb William

  公开号：US20120115722A1

  公开（公告）日：2012-05-10

  Disclosed are compositions comprising (a) at least one compound selected from compounds of Formula 1, N-oxides, and salt thereof, wherein R 1 is phenyl optionally substituted with up to 5 substituents independently selected from R 3 , or pyridinyl optionally substituted with up to 4 substituents independently selected from R 3 ; R 2 is C 1 -C 4 haloalkyl; or thiazolyl, pyridinyl or pyrimidinyl, each optionally substituted with up to 2 substituents independently selected from the group consisting of halogen and C 1 -C 4 alkyl; each R 3 is independently halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy, C(R 4 )═NOR 4 or Q; each R 4 is independently C 1 -C 4 alkyl; Z is CH═CH or S; and each Q is independently phenyl or pyridinyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy and C 1 -C 4 haloalkoxy; and (b) at least one invertebrate pest control agent. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a composition of the invention.

  本发明涉及一种组合物，包括（a）至少一种选择自式1化合物，N-氧化物和其盐的化合物，其中R1是苯基，可选地取代最多5个独立选择自R3的取代基，或者是吡啶基，可选地取代最多4个独立选择自R3的取代基；R2是C1-C4卤代烷基；或噻唑基，吡啶基或嘧啶基，每个基可选地取代最多2个独立选择自卤素和C1-C4烷基的基团；每个R3是独立的卤素，氰基，C1-C4烷基，C1-C4卤代烷基，C1-C4烷氧基，C1-C4卤代烷氧基，C（R4）═NOR4或Q；每个R4是独立的C1-C4烷基；Z是CH═CH或S；每个Q是独立的苯基或吡啶基，可选地取代最多3个独立选择自卤素，氰基，C1-C4烷基，C1-C4卤代烷基，C1-C4烷氧基和C1-C4卤代烷氧基的基团；和（b）至少一种无脊椎动物害虫控制剂。本发明还涉及一种控制无脊椎动物害虫的方法，包括用本发明组合物的生物有效量接触无脊椎动物害虫或其环境。
• MESOIONIC PESTICIDES
  申请人：Holyoke, JR. Caleb William

  公开号：US20100323887A1

  公开（公告）日：2010-12-23

  Disclosed are compounds of Formula 1, wherein X is O or S; Y is O or S; and R 1 , R 2 , R 3 and R 4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

  本发明涉及一种公式1的化合物，其中X为O或S；Y为O或S；R1、R2、R3和R4如所述。本发明还涉及含有公式1的化合物的组合物，以及控制无脊椎动物害虫的方法，包括与本发明的化合物或组合物的生物有效量接触该无脊椎动物害虫或其环境。
• Nuclear medicine diagnostic imaging agent
  申请人：Kyoto University

  公开号：US10029022B2

  公开（公告）日：2018-07-24

  Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where Y, L1, R1 and R2 are as defined.

  本发明提供了一种能够检测表皮生长因子受体二次突变的放射性标记化合物，该化合物由式（1）或其药学上可接受的盐表示，其中 Y、L1、R1 和 R2 如所定义。